Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine

Data ReadoutpositiveAnnamycinPositive

AI Analysis

Summary

Moleculin announced publication of a peer-reviewed cardiac safety analysis of Annamycin showing no clinical or subclinical cardiotoxicity at cumulative doses exceeding traditional anthracycline limits across five pooled clinical trials.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Pooled analysis of five clinical trials found no clinical or subclinical evidence of cardiotoxicity at cumulative doses exceeding traditional anthracycline limits

Importance:5/10

Sentiment:

0.70

cardiac safetycardiotoxicityanthracyclinepeer-reviewed publicationpooled analysis

Related Companies

$SHWZ

Read the original article

Published by GlobeNewswire Pharma on September 28, 2026 11:00 AM

Read Original